I'm really annoyed as a lot of the spec biotechs on my watchlist are going nuts e.g. MEM, ESE, MXC.
ANP was cheap IMO though, valued at spec level when it has a Phase II asset.
It would be interesting to have a look at a current top 20 to see if there are any changes...
Nice work ST. You might be able to pick it up lower if the directors don't capitalise on this mini biotech boom going on atm.
I'm really annoyed as a lot of the spec biotechs on my watchlist...
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.47 |
Change
-0.030(0.86%) |
Mkt cap ! $708.4M | |||
| Open | High | Low | Value | Volume |
| $3.52 | $3.52 | $3.45 | $1.020M | 293.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4646 | $3.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.47 | 10303 | 1 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| ACL (ASX) Chart |
